Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Sanchita Rauth

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2441-8546; OpenAlex author ID A5024831426. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 5 papers · 2022: 6 papers · 2023: none · 2024: 4 papers · 2025: none · 2026: 3 papers

Papers 21

  1. Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218276↗
  2. SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2026.117387↗
  3. Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-026-03896-5↗
  4. Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2024.101146↗
  5. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00562-5↗
  6. Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis. Co-author DOI 10.1053/j.gastro.2023.12.018↗
  7. PAF1/HIF1α axis rewires the glycolytic metabolism to fuel aggressiveness of pancreatic cancer. Co-author DOI 10.1186/s40170-024-00354-2↗
  8. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215922↗
  9. Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2022.03.022↗
  10. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  11. PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer. Co-author DOI 10.1038/s41419-022-05258-x↗
  12. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance. Co-author DOI 10.1053/j.gastro.2021.09.017↗
  13. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. Co-author DOI 10.1158/1541-7786.mcr-21-0888↗
  14. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-020-01518-2↗
  15. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-020-01564-w↗
  16. MASTL regulates EGFR signaling to impact pancreatic cancer progression. Co-author DOI 10.1038/s41388-021-01951-x↗
  17. SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00135-21↗
  18. Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness. Co-author DOI 10.1158/0008-5472.can-20-1293↗
  19. RNA Polymerase II-Associated Factor 1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions With PHF5A a… First author DOI 10.1053/j.gastro.2020.07.053↗
  20. Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1. Co-author DOI 10.1053/j.gastro.2018.05.041↗
  21. Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells. Co-author DOI 10.1186/s12885-018-5074-2↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 21 shared papers, 2018–2026 · strength 3.09
  2. Moorthy Palanimuthu Ponnusamy · 20 shared papers, 2018–2026 · strength 2.96
  3. Ashu Shah · 10 shared papers, 2021–2026 · strength 1.63
  4. Palanisamy Nallasamy · 10 shared papers, 2020–2026 · strength 1.55
  5. Jesse L. Cox · 9 shared papers, 2021–2026 · strength 1.52
  6. Rama Krishna Nimmakayala · 11 shared papers, 2018–2024 · strength 1.37
  7. Saravanakumar Marimuthu · 7 shared papers, 2021–2026 · strength 1.16
  8. Zahraa Wajih Alsafwani · 5 shared papers, 2024–2026 · strength 1.10
  9. Kavita B. Mallya · 7 shared papers, 2021–2026 · strength 1.05
  10. Pranita Atri · 8 shared papers, 2018–2024 · strength 1.02
  11. Satyanarayana Rachagani · 9 shared papers, 2018–2024 · strength 0.97
  12. Parthasarathy Seshacharyulu · 7 shared papers, 2018–2026 · strength 0.96
  13. Koelina Ganguly · 6 shared papers, 2021–2024 · strength 0.91
  14. Subodh M. Lele · 6 shared papers, 2018–2026 · strength 0.85
  15. Venkatesh Varadharaj · 4 shared papers, 2022–2026 · strength 0.85
  16. Sushil Kumar K · 6 shared papers, 2021–2024 · strength 0.82
  17. Lynette M. Smith · 7 shared papers, 2018–2024 · strength 0.81
  18. Geoffrey A. Talmon · 5 shared papers, 2018–2026 · strength 0.74
  19. Maneesh Jain · 5 shared papers, 2021–2024 · strength 0.73
  20. Frank Leon · 4 shared papers, 2020–2026 · strength 0.59
  21. Nivedeta Krishna Kumar · 3 shared papers, 2022–2026 · strength 0.58
  22. Seema C. Parte · 4 shared papers, 2022–2024 · strength 0.55
  23. Ayoola O. Ogunleye · 3 shared papers, 2022–2024 · strength 0.53
  24. Kirtana Arikath · 2 shared papers, 2026 · strength 0.45
  25. Michael Anthony Hollingsworth · 3 shared papers, 2021–2026 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.